Chronic Kidney Disease (CKD): Practice Essentials, Pathophysiology, Etiology
ipf lung disease :: Article Creator Endeavor Pulls In $132M To Back Cancer, Lung Disease Drugs Endeavor BioMedicines has raised $132.5 million in a Series C round designed to advance its two experimental medicines deeper into clinical testing, the San Diego company announced Wednesday. The round was led by AyurMaya, an affiliate of investment firm Matrix Capital Management. Originally, the company's financing target was between $75 million and $100 million, according to CEO John Hood. But Endeavor upped its expectations after reaching out to investors late last year. Hood and his team found strong interest in a biotech with two drugs in early- and mid-stage testing, suggestive of the current investment climate favoring more mature drug startups. The company revealed positive Phase 2 study results in January while putting its funding together. "We got the luxury of raising on really good clinical data for a disease with high unmet need...